Industry news, page-748

Thanks @DAngel35 - that's my way of looking at it too.
I just sent them the following:

---------

Hello Joel,

Cognisant of how busy you all must be, I'll keep this as brief as I can.

Pursuant to the previous message, I recently became aware that Tryp Therapeutics has patented intravenous delivery of psilocin, the metabolite of psilocybin responsible for the psychedelic effect.

This effectively allows for the goal I mentioned to you: relatively fine control over the intensity of the psychedelic experience during the course of the session.

I am not a lawyer, but my concern is that patents that do not marry this intravenous administration with the other more unique aspects of their methodology might become less commercially viable in the mid term.

Incannex might establish its psiGAD treatment as the standard of care for General Anxiety Disorder, only for Tryp to come along a couple of years later with better results thanks to intra-session modulation of the intensity of the trip.

It seems probable that therapists could learn to recognize various inflection points where basically, the patient is 'telling' them through their speech, behavior, brain activity and other indicators, that they are ready for the experience to be heightened or dialed back. This could lead to significantly optimised outcomes.

So my suggestion is: please consider the legal feasibility of expanding your patent to include intravenous administration of psilocin in conjunction with your existing methodology, and perhaps consider including this method for use in the remaining trials that lie ahead. I doubt Tryp can reserve the IP for intravenous injection of a non-proprietary compound so I'm guessing you could work with that approach as well within the scope of your proprietary method. This way, the competitive moat around your approved therapy would be much larger and would probably dissuade them from spending the millions to try to best your results.

I may be misguided with all this, in which case, please dismiss this as the well-intentioned words of a supportive shareholder.